Develops peptide-based therapeutic drugs targeting hematology and blood disorders. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 14% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $46.0M a year. A small number, but proof the product has real buyers.
There is $567.4M in the vault; even if every debt were paid off, $557.0M would remain.
A loss of $130.1M against $46.0M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 4/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 33/100.
On our five-subject report card, PTGX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: PTGX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.